This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICON Selected As A Preferred Provider For Early Phase Clinical Development By Bristol-Myers Squibb

ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been chosen by Bristol-Myers Squibb Company (NYSE:BMY) as a preferred provider for full-service clinical pharmacology and exploratory clinical studies. This latest agreement with Bristol-Myers-Squibb follows the company’s selection of ICON to provide global support for Bristol-Myers-Squibb’s clinical development pipeline, which was announced in June 2010.

Under the preferred provider agreement for early phase development, ICON will provide a broad range of clinical pharmacology and exploratory clinical trial services including study conduct in ICON's Clinical Pharmacology Units, located in San Antonio, Texas; Omaha, Nebraska; and Manchester, UK. ICON will also provide all supporting scientific services such as protocol design and development, project management, clinical monitoring, medical monitoring / pharmacovigilence, data management, biostatistics, pharmacokinetics and medical writing.

“We are pleased that Bristol-Myers-Squibb has again chosen ICON to bring greater operational efficiencies and high quality science to their drug development programs,” commented Dr. Mario Rocci, President, ICON Development Solutions. “Both companies already have a very successful global partnership for phase II-IV clinical development and central laboratory services and we look forward to demonstrating the same value and efficiencies to Bristol-Myers-Squibb’s early phase clinical programs. Our global network of clinical research units, scientists and project teams, underpinned by world class technology, will drive significant cost savings and productivity.”

About ICON plcICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 7,800 employees, operating from 77 locations in 39 countries.

Further information is available at

DISCLOSURE NOTICE: The information contained in this release is as of August 29, 2011. ICON assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking information about ICON’s strategic partnership with Bristol-Myers Squibb Company, including the potential benefits of the partnership on ICON’s future financial results and condition that involves substantial risks and uncertainties. These risks and uncertainties include, among other things, the risk that the partnership results in more limited provision of services by ICON than expected, that those services do not have the expected financial impact on ICON or that the partnership is terminated.

A further description of risks and uncertainties can be found in ICON’s Annual Report on Form 20-F for the fiscal year ended December 31, 2010 and in its Reports of Foreign Issuer on Form 6-K filed with the US Securities and Exchange Commission.


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,749.33 -49.16 -0.28%
S&P 500 2,084.80 -5.31 -0.25%
NASDAQ 5,103.2750 -24.25 -0.47%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs